☆ 4.7 Letter

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients

BLOOD (2018)

Get Full Text
Add to Collection

Journal

BLOOD
Volume 132, Issue 24, Pages 2608-2612

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2018-07-863241

Keywords

-

Categories

Hematology

Funding

  1. National Cancer Institute, National Institutes of Health [R01 CA205954]
  2. Leukemia and Lymphoma Society
  3. International Waldenstrom Macroglobulinemia Foundation
  4. Michele & Stephen Kirsch Fund for Waldenstrom Macroglobulinemia
  5. NATIONAL CANCER INSTITUTE [R01CA205954] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.